Casandra
Casandra Test Code QD09788Version 1 (DRAFT)
Performing Lab
JAK2 Exon 12 Mutation Analysis
Also known as: Myeloproliferative neoplasm, PMF, Essential Thrombocythemia (ET), Polycythemia Vera (PV), ET
Clinical Use
Order TestUse
This DNA‑based assay detects mutations in exon 12 of the JAK2 gene, useful for diagnosing myeloproliferative neoplasms, particularly in patients negative for the more common JAK2 V617F variant. It aids in confirming diagnoses such as polycythemia vera in V617F‑negative cases.
Special Instructions
Not provided.
Limitations
Not provided.
Test Details
Methodology
NGS
Biomarkers
Targets not provided.
Result Turnaround Time
5-7 days
Related Documents
For more information, please review the documents below
Specimen Requirements
Specimen
Whole Blood
Volume
5.0 mL
Minimum Volume
3.0 mL
Container
Lavender Top Tube - EDTA
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 7 days |
Related Tests
Other tests from different labs that may be relevant
JAK2 Exon 12, 13, 14 and 15 Mutation Analysis by NGS
Labcorp
JAK2 Extended (Exon 12-15 non-V617F) Mutation Analysis by NGS
NeoGenomics
JAK2 Exon 12 Mutation Analysis by PCR (Change effective as of 10/20/25: Refer to 3020079 in the October Hotline)
ARUP Laboratories
JAK2V617F Mutation Analysis, Quantitative, With Reflex to JAK2 Exon 12-15 Mutation Analysis by NGS
Labcorp
JAK2 (V617F) Mutation by ddPCR, Qualitative With Reflex to JAK2 Exon 12-Mutation Analysis by PCR
ARUP Laboratories
MPN JAK2 V617F with Sequential Reflex to JAK2 Exon 12-15, CALR, and MPL
NeoGenomics
Polycythemia Vera, JAK2 V617F with Reflex to JAK2 Exon 12-15, Sequencing for Erythrocytosis, Varies
Mayo Clinic Lab
JAK2V617F Mutation Analysis, Qualitative
Labcorp
JAK2V617F Mutation Analysis, Quantitative With Reflex to CALR Mutation Analysis, JAK2 Exon 12-15 Mutation Analysis and MPL Mutation Analysis by NGS
Labcorp
JAK2 V617F Mutation Analysis
MPLN